Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016
Phase 2CompletedDevelopment Stage
Microsatellite Unstable Colorectal Cancer
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
Mar 12, 2014 → Oct 22, 2024
About Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016
Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016 is a phase 2 stage product being developed by Bristol Myers Squibb for Microsatellite Unstable Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02060188. Target conditions include Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02060188 | Phase 2 | Completed |
Competing Products
11 competing products in Microsatellite Unstable Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| MK-3475 + INCB024360 | Merck | Phase 1/2 | 41 |
| AMG 436 | Amgen | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Copanlisib + Nivolumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| Balstilimab + Botensilimab | Agenus | Phase 2 | 44 |